India, Jan. 13 -- A division bench of the Delhi High Court on Monday permitted drugmaker Zydus Lifesciences to sell and market a biosimilar version of the anti-cancer medication Nivolumab in India, setting aside a single judge order that had temporarily restrained the firm from doing the same.

A bench of justices C Hari Shankar and Om Prakash Shukla vacated the July 2025 injunction in a patent infringement suit filed by E.R. Squibb & Sons LLC, which sells the Nivoiumab under the brand Opdivo, restraining Zydus from manufacturing its biosimilar, ZRC-3276.

Nivolumab is a monoclonal antibody-based immunotherapy used in the treatment of several cancers, including lung and head-and-neck cancers, particularly in situations where chemotherapy ...